IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Nitrosamine Impurities in Pharmaceutical Products: Sources, Detection, and Regulatory Perspectives

[1]Khushi M. Naik,[2] Kalapna G. Patel

[1]M. Pharm Research Scholar,[2]Professor

[1]Department of Regulatory Affairs, Anand Pharmacy College, Anand, Gujarat,

Abstract

Nitrosamine impurities have emerged as a significant safety concern in the pharmaceutical industry due to their potential mutagenic and carcinogenic properties. These compounds belong to the class of N-nitroso derivatives that may form during various stages of pharmaceutical manufacturing, including active pharmaceutical ingredient (API) synthesis, formulation, and storage. The detection of nitrosamine impurities such as N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) in several medicinal products has prompted extensive regulatory scrutiny and product recalls worldwide. Nitrosamines can originate from multiple sources, including contaminated raw materials, degradation reactions, solvent impurities, and interactions between drug substances and excipients. To ensure patient safety, regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Council for Harmonisation (ICH) have issued guidelines for risk assessment, detection, and control of these impurities. Advanced analytical techniques, including gas chromatography–mass spectrometry (GC-MS), liquid chromatography–mass spectrometry (LC-MS/MS), and high-performance liquid chromatography (HPLC), are widely employed for the identification and quantification of nitrosamines at trace levels. This review discusses the chemical characteristics, formation mechanisms, potential sources, analytical detection methods, regulatory requirements, and mitigation strategies related to nitrosamine impurities in pharmaceutical products.

Keywords: Nitrosamine impurities, NDMA, NDEA, pharmaceutical contamination, mutagenic impurities, regulatory guidelines, analytical detection.

1. Introduction

The presence of impurities in pharmaceutical products has always been an important consideration in ensuring drug safety and quality. Among these impurities, nitrosamines have received significant attention due to their potential carcinogenic risk. Nitrosamines belong to a group of N-nitroso compounds formed by the reaction of amines with nitrosating agents. Many nitrosamines have been classified as probable human carcinogens based on toxicological studies conducted in laboratory animals.

Nitrosamines are not entirely new to science, as they have been detected in food products, drinking water, tobacco smoke, and industrial chemicals. However, their detection in pharmaceutical products raised serious concerns because medicinal products are consumed regularly by patients over extended periods. The global pharmaceutical community became aware of this issue in 2018 when NDMA was detected in certain batches of valsartan, a commonly used antihypertensive medication belonging to the angiotensin II receptor blocker (ARB) class. This discovery triggered a series of product recalls and investigations across the pharmaceutical industry.

Subsequent studies revealed that other nitrosamines such as NDEA, NDIPA, and NMBA could also be present in drug products. These findings prompted regulatory authorities to conduct comprehensive risk assessments and introduce strict control strategies to minimize nitrosamine contamination.

Nitrosamine impurities may arise from several pathways, including chemical reactions during API synthesis, degradation processes, contaminated solvents, or interactions between excipients and drug substances. In addition, environmental conditions such as temperature, pH, and the presence of catalysts may influence nitrosamine formation.

This review article provides an overview of nitrosamine impurities in pharmaceutical products, focusing on their **chemical characteristics, formation mechanisms, potential sources, analytical detection techniques, and regulatory perspectives**. Understanding these aspects is essential for developing effective strategies to ensure the safety and quality of pharmaceutical medicines.

2. Chemistry and Structure of Nitrosamines

2.1 Structural Characteristics

Nitrosamines are characterized by the presence of the nitroso functional group (–N=O)attached to a nitrogen atom. The general chemical structure of nitrosamines can be represented as:

R_1–N (–R_2)–N=O

Where R_1 and R_2 represent alkyl or aryl groups attached to the nitrogen atom.

The nitroso group is responsible for the biological activity of these compounds. Many nitrosamines exhibit mutagenic and carcinogenic effects because they can undergo metabolic activation in the body to form reactive intermediates capable of damaging DNA.

2.2 Physicochemical Properties

The physical and chemical properties of nitrosamines depend on the nature of their substituent groups. Most nitrosamines detected in pharmaceutical products are relatively small molecules with moderate polarity. These compounds typically exhibit good solubility in both aqueous and organic solvents, which facilitates their distribution in pharmaceutical formulations.

Common nitrosamine impurities include:

- N-Nitrosodimethylamine (NDMA)
- N-Nitrosodiethylamine (NDEA)
- N-Nitrosodiisopropylamine (NDIPA)
- N-Nitrosoethylisopropylamine (NEIPA)
- N-Nitrosodi-n-butylamine (NDBA)
- N-Nitrosomethylethylamine (NMEA)
- N-Nitrosodi-n-propylamine (NDPA)
- N-Nitroso-N-methyl-4-aminobutyric acid (NMBA)

3. Mechanisms of Nitrosamine Formation

3.1 Primary Formation Pathway

The primary mechanism of nitrosamine formation involves the reaction between secondary amines and nitrosating agents such as nitrites. Under acidic conditions, nitrite ions convert into nitrous acid, which generates reactive species capable of reacting with amine groups to form nitrosamines.

3.2 Secondary Formation Routes

Nitrosamines can also form through additional pathways such as:

- Degradation of tertiary amines followed by nitrosation
- Reaction between primary amines and nitrite ions
- Decomposition of nitrosamino acid intermediates
- Nitrosation reactions induced by nitrogen oxides present in the atmosphere

3.3 Environmental and Process Factors

The formation of nitrosamines is influenced by several environmental conditions, including temperature, pH, and catalytic metal ions. Acidic environments promote nitrosation reactions because they facilitate the formation of nitrous acid from nitrite ions.

Metal ions such as copper and iron may act as catalysts, accelerating the reaction by stabilizing intermediate species.

3.4 Solvent-Mediated Formation

Certain solvents used during pharmaceutical manufacturing may contribute to nitrosamine formation. For instance, N,N-dimethylformamide (DMF) may degrade under specific conditions to generate dimethylamine, which can react with nitrosating agents to produce NDMA. Similar mechanisms may occur with solvents such as dimethylacetamide (DMAc) and N-methylpyrrolidone (NMP).

4. Sources of Nitrosamine Impurities

Nitrosamine contamination may arise from multiple sources during pharmaceutical manufacturing processes.

Major sources include:

1. Raw materials containing nitrite impurities
2. Solvents and reagents used during API synthesis
3. Recycled or recovered solvents
4. Degradation reactions during storage
5. Interaction between drug substances and excipients
6. Contamination from packaging materials
7. Environmental exposure to nitrogen oxides

Understanding these sources is essential for designing appropriate mitigation strategies.

5. Analytical Methods for Detection

Accurate detection of nitrosamine impurities requires highly sensitive analytical methods because their acceptable intake limits are extremely low.

5.1 Gas Chromatography–Mass Spectrometry (GC-MS)

GC-MS is widely used for the detection of volatile nitrosamines due to its high sensitivity and selectivity.

5.2 Liquid Chromatography–Mass Spectrometry (LC-MS/MS)

LC-MS/MS provides excellent sensitivity for the analysis of non-volatile nitrosamines and is commonly used for routine pharmaceutical testing.

5.3 High-Performance Liquid Chromatography (HPLC)

HPLC methods are employed for the separation and quantification of nitrosamines in pharmaceutical formulations.

6. Regulatory Perspectives

The detection of nitrosamine impurities in pharmaceuticals led to the development of strict regulatory guidelines worldwide.

Major regulatory authorities include:

- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- International Council for Harmonisation (ICH)

These agencies require pharmaceutical manufacturers to:

- Conduct risk assessments
- Perform confirmatory analytical testing
- Implement mitigation strategies
- Establish specification limits for nitrosamine impurities

Acceptable intake limits for common nitrosamines such as NDMA and NDEA have been established to minimize potential health risks.

7. Control and Mitigation Strategies

Pharmaceutical companies have implemented several strategies to reduce the risk of nitrosamine contamination:

- Careful selection and testing of raw materials
- Limiting nitrite levels in excipients and water
- Avoiding reuse of contaminated solvents
- Optimization of manufacturing processes
- Implementation of sensitive analytical monitoring systems
- Evaluation of drug-excipient compatibility

These strategies help ensure that nitrosamine levels remain within acceptable regulatory limits.

8. Future Perspectives

Ongoing research is focused on improving the understanding of nitrosamine formation mechanisms and developing more sensitive analytical techniques. Advances in pharmaceutical manufacturing technology and quality control practices will further reduce the risk of nitrosamine contamination in medicines.

9. Conclusion

Nitrosamine impurities have become a major concern in pharmaceutical manufacturing due to their potential carcinogenic effects. Their formation can occur through various chemical reactions involving amines and nitrosating agents during drug synthesis, formulation, or storage. Regulatory authorities have introduced strict guidelines to monitor and control these impurities in pharmaceutical products. Continued research and improved quality control measures are essential to ensure the safety and efficacy of medicines.

Reference

1. U.S. Food and Drug Administration. **Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry**. Silver Spring (MD): FDA; 2024. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs

2. U.S. Food and Drug Administration. **Information about Nitrosamine Impurities in Medications**. FDA; 2024. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications

3. World Health Organization. **Information Note: Nitrosamine Impurities in Medicines**. Geneva: WHO; 2019. Available from: https://www.who.int/news-room/detail/20-11-2019-information-note-nitrosamine-impurities

4. Charoo NA, Dharani S, Khan MA, Rahman Z. **Nitroso impurities in drug products: An overview of risk assessment, regulatory milieu and control strategy**. *AAPS PharmSciTech*. 2023;24(2):60. doi:10.1208/s12249-023-02523-w.

5. Akkaraju H, Tatia R, Mane SS, Khade AB, Dengale SJ. **A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products**. *Regul Toxicol Pharmacol*. 2023;139:105355. doi:10.1016/j.yrtph.2023.105355.

6. Bhirud D, Agrawal G, Shah H, Patel A, Palkar MB, Bhattacharya S, et al. **Nitrosamine impurities in pharmaceuticals: Detection, mechanisms and regulatory approaches**. *Curr Pharm Anal*. 2024;24(6):503-522. doi:10.2174/0115680266278636240125113509.

7. Pardeshi N, Satapara V, Patel K. **Nitrosamine contamination in pharmaceuticals: Regulatory perspectives and control strategies of USFDA, EMA and HC**. *Int J Drug Regul Aff*. 2024;12(1). Available from: https://www.ijdra.com/index.php/journal/article/view/624

8. Dobariya U, Chauhan N, Patel H, Pardeshi N. **Nitrosamine impurities: Origin, control and regulatory recommendations**. *Int J Drug Regul Aff*. 2021;9(2). Available from: https://www.ijdra.com/index.php/journal/article/view/472

9. Jena M, Mukadam M, Telange D, Dolas R, Ramaa CS. **Nitrosamine impurities: Assessing concerns through case studies**. *Asian J Chem*. 2023;35(4). doi:10.14233/ajchem.2023.27603.

10. Shekhar NR, Nagappan K, Singh MT, Dhanabal SP. **Nitrosamine impurities in herbal formulations: A review of risks and mitigation strategies**. *Drug Res*. 2023;73(8):431-440. doi:10.1055/a-2081-4232.

11. International Council for Harmonisation (ICH). **ICH Guideline M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals**. Geneva: ICH; 2017. Available from: https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf

12. European Medicines Agency. **Nitrosamine impurities in human medicinal products – assessment report**. EMA; 2020. Available from: https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf

13. U.S. Food and Drug Administration. **Laboratory analysis of valsartan products**. FDA; 2019. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-analysis-valsartan-products

14. U.S. Food and Drug Administration. **Updates on mitigation strategies for nitrosamine drug substance-related impurities**. FDA; 2021. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/updates-possible-mitigation-strategies-reduce-risk-nitrosamine-drug-substance-related-impurities

15. World Health Organization. **WHO technical report series on pharmaceutical impurities and contaminants**. Geneva: WHO; 2020.

16. International Agency for Research on Cancer (IARC). **IARC monographs on the evaluation of carcinogenic risks to humans**. Lyon: IARC; 2018.

17. Hrithika JC, Buggana SJ, Tirunagari M. **Review on nitrosamine impurity: Sources, analytical methods and carcinogenicity**. *Indo Am J Pharm Sci*. 2023;10(8).

18. Schlingemann J, Burns MJ, et al. **Landscape of potential small and drug-substance related nitrosamines in pharmaceuticals**. *J Pharm Sci*. 2022.

19. U.S. Department of Health and Human Services. **Report on Carcinogens**. National Toxicology Program; 2017.

20. European Directorate for the Quality of Medicines (EDQM). **EDQM response to nitrosamine contamination in medicines**. Available from: https://www.edqm.eu